CD19 and marginal zone lymphoma: The ZUMA-5 study was a phase 2, multicenter, single-arm trial that evaluated the efficacy and safety of axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 CAR T-cell therapy, in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL), including FL and marginal zone lymphoma (MZL).